摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate) | 1609067-49-3

中文名称
——
中文别名
——
英文名称
4-oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate)
英文别名
7,8-Bis(((methylamino)carbonyl)oxy)-2-phenyl-4H-1-benzopyran-4-one;[8-(methylcarbamoyloxy)-4-oxo-2-phenylchromen-7-yl] N-methylcarbamate
4-oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate)化学式
CAS
1609067-49-3
化学式
C19H16N2O6
mdl
——
分子量
368.346
InChiKey
NWWRHMSYZTWUBD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    27
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    103
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    7,8-二羟基黄酮衍生物的晶型B及其制备方法、应用
    摘要:
    本发明公开了一种7,8‑二羟基黄酮衍生物的晶型B及其制备方法、应用。其在使用辐射源为Cu‑Kα的粉末X射线衍射光谱中,在衍射角2θ=7.294°、9.622°、11.061°、17.079°、22.167°、22.404°、23.805°、26.642°、29.188°、32.759°处有特征衍射峰,2θ误差范围为±0.2。本发明晶型B高湿条件下具有较好的稳定性、极低的吸湿性以及较高的生物利用度,且制备方法简单,对药物的优化和开发具有重要的价值。
    公开号:
    CN114075162A
点击查看最新优质反应信息

文献信息

  • [EN] Substituted Dihydroxyflavone Derivatives, Compositions, and Methods Related Thereto<br/>[FR] DÉRIVÉS DE DIHYDROXYFLAVONE SUBSTITUÉS, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
    申请人:UNIV EMORY
    公开号:WO2020033960A1
    公开(公告)日:2020-02-13
    In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof.
    在某些实施例中,该公开涉及杂环黄酮衍生物,例如本文提供的公式所描述的那些,制药组合物,以及相关方法。在某些实施例中,该公开涉及治疗或预防与BDNF和TrkB活性相关的疾病或症状的方法,如抑郁症、中风、雷特综合征、帕金森病和阿尔茨海默病,通过向需要的受试者投与本文披露的化合物组成的制药组合物的有效量。
  • [EN] 7,8-DIHYDOXYFLAVONE AND 7,8-SUBSTITUTED FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO<br/>[FR] 7,8-DIHYDROXYFLAVONE ET DÉRIVÉS DE FLAVONE 7,8-SUBSTITUÉE, COMPOSITIONS ET MÉTHODES ASSOCIÉES
    申请人:UNIV EMORY
    公开号:WO2014071134A1
    公开(公告)日:2014-05-08
    In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
    在某些实施例中,本公开涉及7,8-二羟基黄酮和7,8-取代黄酮衍生物,例如本文提供的公式所描述的那些,以及与之相关的药物组合物和方法。在某些实施例中,本公开涉及治疗或预防与BDNF和TrkB活性相关的疾病或症状的方法,例如精神疾病、抑郁症、创伤后应激障碍和自闭症谱系障碍、中风、莱特综合征、帕金森病和阿尔茨海默病,通过向需要的受试者施用包含本文披露的化合物的药物组合物的有效量。在某些实施例中,考虑到本文披露的7,8-取代黄酮衍生物是7,8-二羟基黄酮和类似物的前药。
  • 7,8-DIHYDROXYFLAVONE AND 7,8-SUBSTITUTED FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO
    申请人:Emory University
    公开号:EP2914585B1
    公开(公告)日:2018-03-07
  • 7,8-DIHYDOXYFLAVONE AND 7,8-SUBSTITUTED FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO
    申请人:Emory University
    公开号:EP2914585A1
    公开(公告)日:2015-09-09
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION
    申请人:Pharmatrophix, Inc.
    公开号:US20220031641A1
    公开(公告)日:2022-02-03
    Provided are compositions and methods comprising agonists. Also disclosed are agonist compounds, pharmaceutical compositions of agonists, and methods of using the same.
查看更多